A Crisis in the Treatment of Osteoporosis - 10 Years Later, the US Care Gap is Still Open

Clicks: 10
ID: 339342
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #146 of 148 articles by views in journal of bone and mineral research : the official journal of the american society for bone and mineral research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 148 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
A decade ago, we published an editorial in the Journal of Bone and Mineral Research describing a crisis in osteoporosis treatment. In this Perspective, we reassess osteoporosis care and progress addressing that crisis. Despite the availability of safe and effective medications that reduce fracture risk, the osteoporosis care gap persists and may have widened in the United States (US). Fewer than 15% of patients receive osteoporosis therapy within one year of a fragility fracture, and treatment rates declined between 2015 and 2022. Meanwhile, declining hip fracture rates plateaued around 2012 and remain stable, while clinical vertebral fractures have increased. Persistent barriers include limited patient awareness of bone health, low screening rates, reduced access to dual-energy X-ray absorptiometry (DXA), concerns regarding treatment-related adverse events, underutilization of fracture liaison services, as well as racial, ethnic, and socioeconomic disparities. Despite this, the tools available to address the crisis have expanded. Advances that can help narrow the current care gap include new osteoanabolic agents; improved understanding of atypical femur fracture risk-benefit profiles; goal-directed treatment; opportunistic screening and diagnosis; artificial intelligence-enabled vertebral fracture detection; and electronic medical record-based decision support. Other developments may reduce the future burden of osteoporosis and fracture, including growing evidence supporting primary prevention, evolving perspectives on menopausal hormone therapy, and U.S. Food and Drug Administration qualification of total hip bone mineral density as a surrogate endpoint for fractures, which may facilitate more efficient drug development. The challenge now is to implement available approaches for patients at high fracture risk while continuing to consider strategies that shift osteoporosis care toward earlier prevention. Progress will require coordinated action by healthcare systems, providers, payers, professional societies, and policymakers to improve equitable access to fracture prevention.
Reference Key
openalex_W7225710205 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal journal of bone and mineral research : the official journal of the american society for bone and mineral research
Year 2026
DOI
10.1093/jbmr/zjag157
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.